Sangamo Therapeutics (SGMO) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings or view top-rated stocks.

5 analysts have issued twelve-month price objectives for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $16.00. On average, they predict the company's stock price to reach $8.91 in the next twelve months. This suggests a possible upside of 675.2% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.

Sangamo Therapeutics' stock was trading at $3.14 at the beginning of the year. Since then, SGMO stock has decreased by 63.4% and is now trading at $1.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SGMO earnings forecast.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its quarterly earnings results on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company had revenue of $27.23 million for the quarter, compared to analyst estimates of $26.86 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 40.44% and a negative net margin of 52.76%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.26) EPS.

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA) and SPDR S&P Biotech ETF (XBI).

Sangamo Therapeutics updated its first quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$158.00 million.

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.22%), Wasatch Advisors LP (7.94%), State Street Corp (5.21%), Credit Suisse AG (2.23%), Dimensional Fund Advisors LP (1.92%) and Renaissance Technologies LLC (1.88%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends.

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGMO stock can currently be purchased for approximately $1.15.

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $197.60 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 431 workers across the globe.

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.